Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study

Published:2009-06 Issue:3 Volume:113 Page:341-347
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Farley John,Fuchiuji Sartoru,Darcy Kathleen M.,Tian Chunqiao,Hoskins William J.,McGuire William P.,Hanjani Parviz,Warshal David,Greer Benjamin E.,Belinson Jerome,Birrer Michael J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference39 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J. Clin.,2008

2. Cancer of the ovary;Young,1993

3. Her2 oncogene amplification in stage I and stage III ovarian papillary serous carcinoma;Afify;Exp. Mol. Pathol.,1999

4. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization;Young;Genes Chromosomes Cancer,1996

5. Overexpression of Her2 is associated with poor survival in advanced epithelial ovarian cancer;Berchuck;Cancer Res.,1990

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Molecular Therapy for Ovarian Cancer Patients;Advances in Diagnosis and Management of Ovarian Cancer;2022

2. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling;Cancer Research;2020-10-21

3. Translational Theragnosis of Ovarian Cancer: where do we stand?;Current Medicinal Chemistry;2020-10-11

4. The emerging role of precision medicine in the treatment of ovarian cancer;Expert Review of Precision Medicine and Drug Development;2020-06-16

5. Afatinib use in recurrent epithelial ovarian carcinoma;Gynecologic Oncology Reports;2019-08